Using Tempol to reduce side effects from cancer treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of Tempol in preventing or reducing toxicities associated with cisplatin and radiation therapy in patients with head and neck cancer. Over a 10-week period, 120 participants will be monitored for mucositis, nephrotoxicity, and ototoxicity, which are common side effects of these treatments. The study will compare the outcomes of those receiving Tempol against a placebo to determine its potential benefits in improving patient quality of life and treatment adherence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be ≥18 years of age with medically diagnosed squamous cell cancer of the head and neck (SCCHN);
2. Be scheduled to receive radiotherapy or proton therapy administered with a curative intent;
3. If female and of child bearing potential, be using an effective birth-control method with a history of reliability for the individual participant;
4. If male and of child bearing potential, adequate methods of contraception must be employed including use of condoms with spermicide. No sperm donation for 90 days until after the conclusion of the study;
5. Must be receiving cisplatin for chemotherapy;
6. Be properly informed of the nature and risks of the clinical investigation, comply with all clinical investigation-related procedures, and sign an Informed Consent Form prior to entering the clinical investigation;
7. Must have a score 2 or less on the ECOG performance status;
8. Participant life expectancy ≥ 6 months; and
9. Adequate baseline organ function (hematologic, liver, renal, nutritional and metabolic):

Haematology:

Absolute neutrophil count (ANC) ≥1.5 Hemoglobin ≥ 10 g/dL Platelets ≥ 100,000 per microliter of blood

Hepatic:

Total bilirubin ≤ 2 X (Upper limit normal) ULN Alanine amino transferase (ALT) and Aspartate aminotransferase (AST) ≤5 x ULN

Renal:

Serum creatinine ≤ ULN or, if \> ULN calculated creatinine clearance (CrCl) ≥ 60 mL/min.

Nutritional and metabolic:

Urine Albumin \< 3.0 mg/dl

Exclusion Criteria:

1. Prior radiotherapy of the head and neck;
2. Have a clinically significant infection defined as any acute viral, bacterial or fungal infection, which requires specific therapy. Anti-infectious therapy must have been completed within 14 days of starting study treatment;
3. Be taking any non-approved therapy for oral mucositis, including β-carotene, tocopherol, laser irradiation, brushing the oral mucosa with silver-nitrate prophylactically, systemic TGF-β (transforming growth factor beta), or systemic KGF (keratinocyte growth factor) during or within 14 days of starting treatment;
4. Be taking mugard;
5. Be taking prostaglandins, pentoxifylline or leucovorin during or within 14 days of starting treatment;
6. Be rinsing with allopurinol, hydrogen peroxide, sucralfate, or chlorhexidine mouthwashes during or within 14 days of starting treatment;
7. Have had a recent, serious, non-malignant medical complication that, in the opinion of the investigator, makes the individual unsuitable for study participation;
8. Have used an investigational drug within 28 days of the initiation of study treatment;
9. Have a history of a positive blood test for HIV;
10. At the time of screening, having a significant active medical illness which, in the opinion of the investigator, would preclude completion of the study;
11. Participants with a treatment plan consisting of chemoradiation followed by further chemotherapy;
12. Participants with body weight less than 35 kg, 77 lbs;
13. Women who are pregnant or who are breastfeeding;
14. Participants with known intolerance to platin drugs;
15. History of insulin-dependent Diabetes Mellitus; and
16. Participants with Hepatitis B/C.

Where it's running

• UCSD
  La Jolla, California, United States Recruiting
• Mercy Medical Center
  Merced, California, United States Recruiting
• Central Coast Medical Oncology
  Santa Maria, California, United States Recruiting
• Mission Hope Health Center
  Santa Maria, California, United States Recruiting
• Montefiore Medical Center-Einstein Campus
  The Bronx, New York, United States Recruiting
• Wake Forest University Health Sciences
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Study coordinator: Benji Crane
• Email: bjcrane@matrixbiomed.com
• Phone: 6264376506

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alpha-lipoic acid to help protect kidneys during cisplatin chemotherapy

  This trial will see if taking alpha-lipoic acid can prevent kidney damage in adults receiving cisplatin chemotherapy.

  Recruiting Phase 2 Minia University · Minya, Minya Governorate · NCT07564479

• N-acetylcysteine to prevent cisplatin-related hearing loss

  This study tests whether N-acetylcysteine (NAC) can prevent hearing loss in adults receiving high-dose cisplatin chemotherapy.

  Recruiting Phase 2 Siriraj Hospital · Bangkok, Bangkoknoi · NCT07364747

• L-carnitine to protect kidneys from cisplatin damage

  This trial will test if L-carnitine can help protect the kidneys of adults receiving cisplatin-based chemotherapy.

  Recruiting Phase 2 Tanta University · Shibīn al Kawm · NCT07108777

• Enamel matrix derivatives to thicken gum tissue around dental implants

  We will test whether applying enamel matrix derivatives under the gum flap during implant uncovering makes gum tissue thicker and increases the width of keratinized mucosa in adults getting dental implants.

  Recruiting The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT07053969

• Evaluating kidney and blood pressure outcomes in childhood cancer survivors

  This study is trying to see how common kidney problems and high blood pressure are in childhood cancer survivors a few years after their treatment.

  Recruiting The Hospital for Sick Children · Toronto, Ontario · NCT06153147

• Impact of radiosurgery on hearing and balance in vestibular schwannoma patients

  This study is testing how a specific type of radiation treatment affects hearing and balance in people with vestibular schwannoma.

  Recruiting University Hospital, Geneva · Geneva · NCT05641441

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.